Motilal Oswal's research report on Max Healthcare
Max Healthcare (MAX) delivered in-line performance for 4QFY24. The quarterly EBITDA continues to inch up since the listing (Aug’20), reaching INR4.9b for 4QFY24. Max has demonstrated superior execution across its hospitals, Max Lab, and Max@home segments, supported by a growing number of patients and improved realizations. We reduce our earnings estimate by 4%/5% for FY25/FY26, factoring frontloading of certain operational cost related to addition of beds. We value MAX on SOTP basis (30x EV/EBITDA for hospital business on 12M forward rolling basis, 22x EV/EBITDA for Max Lab, 4x EV/Sales for Max @ Home) to arrive at a price target of INR930.
Outlook
We value MAX on SOTP basis (30x EV/EBITDA for hospital business on 12M forward rolling basis, 22x EV/EBITDA for Max Lab, 4x EV/Sales for Max @ Home) to arrive at a price target of INR930.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
